The INDEPSO-ISPSM Consensus on Peritoneal Malignancies-Methodology

INDEPSO-ISPSM关于腹膜恶性肿瘤的共识——方法学

阅读:1

Abstract

The numerous international guidelines on cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) do not cover many clinically relevant issues for which evidence is limited and some regional issues (HIPEC in limited resource settings, age-limit for CRS, etc.). We describe the methodology of a consensus CRS and HIPEC for peritoneal malignancies carried out under the aegis of the two national societies for peritoneal oncology-INDEPSO and ISPSM. The modified Delphi technique was used with two rounds of voting. Eight key topics were selected by a working group of 29 members. Questionnaires comprising of closed-ended questions were disseminated through the online SurveyMonkey (http://www.surveymonkey.com) platform. A panel of 56 surgical, gastrointestinal, and gynecologic oncologists with a minimum of 5 years of experience with CRS-HIPEC voted on 260 questions. A consensus was reached if any of the options received 70% or more votes (> 90% = strong consensus). The response rate was 98.2% in round I and 94.6% in round II. A consensus was achieved on 80.7% questions after two rounds (43.0% after round I; 36.9% after round II). It was the highest in the enhanced recovery after surgery (ERAS) section (93.3%) and the lowest (68.0%) for ovarian cancer. A strong consensus was reached on 59 (22.6%) questions (highest for  the technical section (34.2%); lowest in the ERAS section (16.6%)). This consensus which had a high rate of participation should be a useful clinical resource for surgeons treating peritoneal malignancies in India and other regions with a similar demographic and socioeconomic background. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13193-024-02118-2.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。